Southlake, TX – According to filings with the U.S. Securities and Exchange Commission, OncoNano Medicine is raising $60,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Driscoll played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OncoNano Medicine
OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and T-cell activating immunotherapies. OncoNano Medicine employs proprietary pH-activated micelles that have been engineered to exploit the universal trait of acidity of solid tumors, known as the Warburg Effect. This approach allows us to specifically deliver molecules to the tumor microenvironment while minimizing exposure to normal tissues. OncoNano Medicine micelles have been demonstrated in in vivo models and in patients to rapidly dissolve releasing payloads precisely in the tumor microenvironment and with superior tumor penetration. Our most advanced program, ONM-100, is currently in Phase 2 trials in multiple solid tumor types. ONM-100 has been developed to provide accurate, real-time imaging of tumors during cancer resection surgery. Our proprietary cancer therapeutic programs include ONM-400, a next-generation IL-2 program that demonstrates a highly differentiated mechanism of action in preclinical studies, and ONM-401, a small molecule program focused on tumor reduction and an improved therapeutic index.

To learn more about OncoNano Medicine, visit http://www.onconanomed.com/

Contact:
Martin Driscoll, Chief Executive Officer
682-285-1411
https://www.linkedin.com/in/marty-driscoll-a315015/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved